Mu-selective, but not non-selective, opioid receptor antagonism reduces L-DOPA induced dyskinesia in the MPTP macaque model of Parkinson's disease

被引：0
|
作者：
Fox, S. H.
Koprich, J. B.
Johnston, T. H.
Goodman, A.
Le Bourdonnec, B.
Dolle, R. E.
DeHaven, R. N.
DeHaven, D. L.
Little, P. J.
Brotchie, J. M.
机构：
来源：
MOVEMENT DISORDERS | 2010年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S412 / S412
页数：1
相关论文
共 50 条
  • [41] Entacapone combined with L-dopa enhances antiparkinsonian activity and avoids dyskinesia in the MPTP-treated primate model of Parkinson's disease (PD)
    Jenner, P
    Al-Barghouthy, G
    Smith, L
    Kuoppamaki, M
    Jackson, M
    Rose, S
    MOVEMENT DISORDERS, 2002, 17 : S57 - S58
  • [42] Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
    Kwan, Cynthia
    Frouni, Imane
    Bedard, Dominique
    Hamadjida, Adjia
    Huot, Philippe
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 871
  • [43] The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease
    Nash, JE
    Ravenscroft, P
    McGuire, S
    Crossman, AR
    Menniti, FS
    Brotchie, JM
    EXPERIMENTAL NEUROLOGY, 2004, 188 (02) : 471 - 479
  • [44] Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia
    Silverdale, MA
    Crossman, AR
    Brotchie, JM
    EXPERIMENTAL NEUROLOGY, 2002, 174 (01) : 21 - 28
  • [45] Animal models of Parkinson's disease and L-dopa induced dyskinesia: How close are we to the clinic?
    Lane, Emma
    Dunnett, Stephen
    PSYCHOPHARMACOLOGY, 2008, 199 (03) : 303 - 312
  • [46] Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
    Bortolanza, Mariza
    Padovan-Neto, Fernando E.
    Cavalcanti-Kiwiatkoski, Roberta
    dos Santos-Pereira, Mauricio
    Mitkovski, Miso
    Raisman-Vozari, Rita
    Del-Bel, Elaine
    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2015, 370 (1672) : 1 - 13
  • [47] Naltrexone reduces behavioural sensitisation to repeated L-DOPA treatment in a rat model of L-DOPA-induced dyskinesia in Parkinsons disease
    Ravenscroft, P
    Brotchie, JM
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2000, 12 : 215 - 215
  • [48] Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?
    Emma Lane
    Stephen Dunnett
    Psychopharmacology, 2008, 199 : 303 - 312
  • [49] Selective Metabotropic Glutamate Receptor 5 (mGlu5) Antagonism Reduces L-DOPA-Induced Dyskinesia in MPTP-Lesioned Primates at the Expense of Anti-Parkinsonian Benefit
    Johnston, Tom H.
    Fox, Susan H.
    Piggott, Matthew J.
    Brotchie, Jonathan M.
    NEUROLOGY, 2010, 74 (09) : A84 - A84
  • [50] Association of the adenosine receptor A2A (ADORA2A) gene with L-dopa induced dyskinesia in Parkinson's disease
    Greenbaum, L.
    Cohen, O. S.
    Inzelberg, R.
    Kaplan, N.
    Yahalom, G.
    Kozlova, E.
    Strauss, H.
    Lerer, B.
    Hassin-Baer, S.
    MOVEMENT DISORDERS, 2012, 27 : S456 - S456
12345